| E-Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Hair Loss > Alopecia Areata Treatment |
|
E-Articles - Alopecia Areata Treatment
There are two main forms of this condition which vary by the extent of hair loss and require different types of alopecia areata treatment. The mild form is where less than 50% of the hair is lost from thinning patches According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product on the scalp and the more severe condition where more than 50% up to 100% of the hair is lost. When diagnosing alopecia areata it is useful to have some background information about the disease. Alopecia areata is k ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in nown as an autoimmune condition that can be highly unpredictable and which affects about 1.7 % of the population. The body’s white blood cells attack the hair follicles resulting in a stop in growth. It usually starts lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. with one or two small round bald patches on the scalp, but can develop into a complete loss of hair, both on the scalp (alopecia totalis) and body (alopecia universalis). It is not known what triggers such attacks, wh here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ether the trigger comes from within, or from outside such as in the form of a virus. Recent research seems to show that some people have genetic markers that increase both their susceptibility to the condition and to d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro its severity. One in five people with the condition will have a relative who is also affected. This is especially true in those who develop the condition before the age of 30. It is more common in families whose memb ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc rs also have conditions such as asthma, hay fever, eczema, thyroid disease, Addison’s disease, rheumatoid arthritis, lupus erythematosus, vitiligo, Addison’s disease or pernicious anaemia. The condition occurs in peo easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ple of all ages and races and can have huge psychological effects which are exacerbated by the fact that the public at large do no generally understand this condition. It is sudden in onset and can recur from time to nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically time quite unpredictably. There is no known cure for alopecia areata and hair loss is a side effect of the underlying disease. Current alopecia areata treatments therefore work by extensive stimulation of the hair fo and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ licles which needs to be continued for the duration of the disease. The mild form of the disease is easier to treat and the most common form of treatment is to have monthly cortisone injections, injected directly int ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi o the bare scalp. These are usually quite painless giving a slight tingling sensation and have very few side effects such as minor skin depressions. This alopecia areata treatment is usually complimented with higher s ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a trength 5% topical minoxidil solution applied twice daily. Cortisone cream is sometimes used in combination with minoxidil for improved response and applied 30 minutes after the minoxidil application. Another effecti dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod e treatment is anthralin cream or ointment, a synthetic, tar-like substance widely used for psoriasis treatment. It is applied to the bare scalp once daily and as it can be a skin irritant is usually only left on for cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin 30-60 minute periods then washed off. Successful treatments can stimulate new hair growth in eight to twelve weeks. Extensive alopecia areata is much more difficult to treat and local injections of cortisone into the tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen scalp are not that effective. In some cases cortisone pills are prescribed, these have a more powerful effect but there is a greater risk of side effects with extended use. In general they are not widely prescribed a t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel art from to young healthy adults who may have higher tolerance levels for the drug. Topical minoxidil at 5% strength is still the most common alopecia areata treatment and effective even for extensive alopecia areata. ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust Another method that is used frequently in Canada and Europe is known as topical immunotherapy. This uses the chemicals diphencyprone (DPCP) or squaric acid dibutyl ester (SADBE) to induce an allergic rash in the scal y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products p. To date topical immunotherapy has been show to be the most effective alopecia areata treatment with 40% of patients regrowing hair after six months of treatment. Sufferers of alopecia areata should not give up ho . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de e of a cure as there are many ongoing research projects are currently being undertaken. Some of the most promising involve gene therapy, stem cells research and hair follicle development and new alopecia areata treatm elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ents will continue to be made available. For more general information about the causes of alopecia please visit our web site tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:9 Steps to Get Out of Debt - Part 9 Can I Get Affordable Dental Care? Ear Pain Relief - Quick and Easy
|